

Immuno Cure Biotech appoints new CEO

Broadening executive leadership team to accelerate growth strategy

(15th April 2022, Hong Kong) – **Immuno Cure BioTech**, a biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines, announced today the appointment of Dr. Xia Jin as new Chief Executive Officer and Executive Director. He has also been invited to join as a member of the co-founding team in their joint investment in Immuno Cure. Former Chief Executive Officer and Co-Founder Mr. Andy Wong will continue acting as Executive Director. Xia Jin, MD PhD, with his vast experience in viral immunology and vaccine development, in particular in AIDS and other infectious diseases, brings to the group new dimension of expertise and capability in propelling further innovative development of our technology platforms. With his leadership, Immuno Cure is poised to broaden the spectrum of our pipeline development and advance into clinical stage of the COVID-19 and AIDS vaccines. Planning ahead, Andy Wong, with his rich experience in manufacturing management, will now be able to dedicate his time and expertise in leading the group into the production phase of our vaccines as well as more emphasis on commercial affairs.

Dr. Percy Cheng, Chairman of Immuno Cure said, “I’d like to welcome Dr. Jin to our Board and his new post of CEO. With his wealth of expertise, he will no doubt strengthen our R&D and clinical capabilities. I am fully confident on his leadership in taking us forward with a healthy growth and maturity of our pipeline candidates, laying solid foundation for our future. Andy Wong has been instrumental in building our team and taking us from startup to clinical stage. He could now focus on striving ahead into the production phase of our evolution.”

Executive Director, Mr. Andy Wong echoed, “I welcome Dr. Jin to our team, leading Immuno Cure for further development and growth. I am proud to have been entrusted by the Board with the team building task and to take the group through the early stage development. I am happy with the talents that we have recruited in the past 18 months who, I believe, will serve as the backbone of Immuno Cure in the

future. From here on, I'll offer my full support to Xia and dedicate my effort in what I do best, which is to develop our downstream capabilities in vaccine production.”

Executive Director and CEO, Dr. Xia Jin said, “I am delighted to be appointed Executive Director and CEO and be charged with the duty to accelerate the transformation of Immuno Cure. I am also excited to participate in the co-founding team’s investment. I am committed to work closely with our fellow directors and take guidance from our Advisory Board. I am confident on the talent and capability of our team that Andy has built and look forward to leading the effort in challenging new heights together.”

Dr C H Leong, Chairman of the Advisory Board concluded, “We are delighted to welcome Dr Jin and look forward to a lasting relationship. With vast experience in virology, immunology and vaccinology, Immuno Cure will hugely benefit from his strong and visionary leadership.”

* * * * *

Notes:

Dr. Xia Jin

Dr. Xia Jin MD PhD, was Chief Scientific Officer and Vice President of Serum Bio Technology (STAR Market : SH688163) in Shanghai. Prior to that, he was Professor and Principal Investigator of Shanghai Public Health Clinical Center and the Director of Vaccine and Immunology Research Center of Fudan University. He was also Distinguished Professor of Chinese Academy of Sciences and Principal Investigator and Executive Director of Vaccine Center at Institut Pasteur of Shanghai. He had been a tenure-track Assistant and Associated Professor at Rochester University, New York, USA. He obtained a Medical Doctor degree after completion of the 8-year Curriculum at Peking Union Medical College and then a PhD degree in Life and Biomolecular Sciences from Open University under the tutelage of Professor Sir Patrick Sissons of Cambridge University Clinical School in UK. His postdoctoral training was completed with Drs. Richard A. Koup and David Da I Ho, respectively at the Aaron Diamond AIDS Research Center in New York. While working in USA, he has been a Principal Investigator or Co-investigator of over research grants from NIH and the Bill & Melinda Gates Foundation. He has served as a member of numerous NIH study sections and also as international expert reviewer for Netherlands, Hong Kong, Taiwan and Singapore research agencies. He has been

the Chair (HVTN-064, HTVN-083) and Co-Chair (HTVN-063, HTVN-094) of HIV vaccines clinical trials conducted by the HVTN of NIH/NIAID in USA. He is an academic Editor of PLoS ONE and Editorial Board Member of JAIDS. His laboratory work focuses on HIV and dengue virus immunology and vaccine development. He has published over 140 SCI papers in Science, J Exp Med, J Clin Inv, J Immunology, J Virol, J Inf Dis, AIDS, Retrovirology, Vaccine.

Mr. Andy Wong

Mr. Andy Wong has over 20 years of management experience in pharmaceutical industry; leading M&A of innovative R&D startup companies in medical device and new drug development; in charge of functions of compliance, quality, manufacturing, R&D project, operation and new plant projects. Prior to joining Immuno Cure, he was the business advisor for a number of biotechnology and biomedical companies, which were supported by funding including China Investment Fund, the Innovative and Technology Fund in Hong Kong, Hong Kong Science Park Incubation Fund and listed pharmaceutical and medical companies in Hong Kong and the Mainland. Andy was Chief Operating Officer, Executive Vice President of Jacobson Pharmaceutical (2633.HK), responsible for the operations of the plants, research and development function and other project with various functions. Prior to that, he was VP in operation management as well as VP General Manager of Compliance and Risk Management in Jacobson. Mr Wong graduated from City University with a bachelor degree in science in analytical chemistry and a master of philosophy in chemistry.

Immuno Cure Biotech

Immuno Cure BioTech is a biotechnology group based in the Hong Kong Science Park, focusing on research and development of vaccines and immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-based DNA vaccine and Anti-PD-1 Isoform Antibody technology platforms.

To learn more about Immuno Cure BioTech, please visit www.immunocure.hk

Media Contact: carolchung@immunocure.hk